Pulmonary Recovery 12 Months after Non-Severe and Severe COVID-19: The Prospective Swiss COVID-19 Lung Study.

"Conflict of Interest Statement Christian Clarenbach received advisory fees from Roche, Novartis, Boehringer, GSK, AstraZeneca, Sanofi, Vifor, OM Pharma, Grifols, and Mundipharma within the last 36 months. Christophe von Garnier obtained advisory fees from AstraZeneca, Boehringer Ingelheim, GSK, Mundipharma, Novartis, OM Pharma, Pfizer, PneumRx and Pulmonx, and Sanofi and received financial support from the Ligue pulmonaire vaudoise, the Yuchum Foundation, and the Placide Nicod Foundation. Manuela Funke-Chambour has received research funding from Boehringer Ingelheim and Roche and advisory fees from Boehringer Ingelheim, MSD, Daiichi Sankyo, and Novartis unrelated to the presented study. Marco Mancinetti received financial support from the University and Hospital of Fribourg, Switzerland, to cover protected time for clinical research. Lise Piquilloud obtained lecture fees for conferences given in scientific symposium for different ventilator manufacturers (Getinge, Hamilton, General Electrics, Fisher, and Paykel). Sebastian Ott is supported by the Lungenliga beider Basel. Sebastian Ott received consulting fees from GSK and honoraria from Novartis and participated in advisory boards for GSK, Boehringer Ingelheim, and Novartis."

"Lungenliga Bern (to MFC), Johanna Dürmüller Foundation (to MFC), Bern Center for Precision Medicine (BCPM) (to MFC), the Federal Office of Public Health (FOPH) of the Federal Council of Switzerland (to MFC), Ligue Pulmonaire Vaudoise (to CvG), Fondation Placide Nicod (to CvG), and Fondation Yuchum (to CvG) contributed to the funding of this study but had no role in its design, conduct, or analysis."

"Patients included in the current analyses were participants of the prospective multicentre observational Swiss COVID-19 lung cohort study (Swiss COVID lung study). Patients were prospectively recruited in 9 centres from May 1, 2020 to December 31, 2021, following acute SARS-CoV-2 infection. Initial findings of this study and details on participating centres have been previously published []. Severe COVID-19 was defined as admission to an ICU and/or a diagnosis of ARDS. This approach considered that ARDS patients were taken care of depending on their severity degree and comorbidities not only in ICU, but also in intermediate care or general wards. Non-severe COVID-19 excluded both ICU admission and ARDS. Patient visits took place at 3, 6, and 12 (+/−2) months after initial COVID-19 symptoms, with dropouts of participants who recovered and no longer required respiratory follow-up. All participants provided written informed consent, and the study was approved by the Central Ethics Committee and the respective Local Cantonal Ethics Committees (KEK 2020-00799). The study is registered at clinicaltrial.gov (NCT04581135)."